NICOLA HANANIA to Salmeterol Xinafoate
This is a "connection" page, showing publications NICOLA HANANIA has written about Salmeterol Xinafoate.
Connection Strength
0.310
-
Ten years of tiotropium: clinical impact and patient perspectives. Int J Chron Obstruct Pulmon Dis. 2013; 8:117-25.
Score: 0.109
-
The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD. Pulm Pharmacol Ther. 2005; 18(1):19-22.
Score: 0.062
-
The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003 Sep; 124(3):834-43.
Score: 0.057
-
The safety of long-acting ?2-agonists in the treatment of stable chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2013; 8:53-64.
Score: 0.027
-
Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance. Ther Adv Respir Dis. 2008 Apr; 2(2):37-48.
Score: 0.019
-
Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin Ther. 2007 Feb; 29(2):261-78.
Score: 0.018
-
Salmeterol stimulation dissociates beta2-adrenergic receptor phosphorylation and internalization. Am J Respir Cell Mol Biol. 2007 Feb; 36(2):254-61.
Score: 0.017